Poging GOUD - Vrij
Innovation Takes Centre Stage in Paediatric healthcare
BioSpectrum Asia
|BioSpectrum Asia July 2024
Children represent approximately one-third of the world's population, with over 580 million in the East Asia and Pacific region alone Source: UNICEF). Historically underrepresented in healthcare care delivery and innovation, the landscape is evolving as governments and healthcare organisations in the region strive to address paediatric healthcare needs. Paediatric healthcare spans recommended immunisations before adulthood to developmental health, mental health, neonatal care and rare diseases, among others. Let's deep dive into the innovations enhancing children’s well being in the region.
Innovations in paediatric healthcare are rapidly advancing in the Asia Pacific region, driven by new technologies and collaborative efforts to improve children's well-being. From cuttingedge medical devices improving preterm births, to technology addressing mental healthcare and advanced genetic screening, Asia Pacific is leaving no stone unturned in its efforts to enhance paediatric care.
Newborn genetic screening is advancing significantly in the region. Traditionally focused on detecting a limited number of rare diseases with early onset and established treatments, such programmes are now integrating genomic sequencing to enhance early detection and intervention.
A pioneering study by Chinese firm BGI Genomics highlights the potential of gene panels as a primary screening tool, benefitting approximately one out of every 500 newborns. This approach is part of broader efforts across the APAC region, where studies like the Epi-Genomic Newborn Screening (EpiGNs) programme in Victoria, Australia, aim to identify conditions linked to intellectual disability, autism, severe obesity, and seizures through genomic analysis as part of routine heel prick tests.
Another study in Australia, the Baby Beyond project, funded by the government, plans to sequence the genomes of 1,000 newborns to screen for around 500 treatable childhood-onset disorders. This initiative builds upon earlier efforts and underscores the potential of integrating genomic data into electronic health records (EHRs) for ongoing healthcare management and research.

Dit verhaal komt uit de BioSpectrum Asia July 2024-editie van BioSpectrum Asia.
Abonneer u op Magzter GOLD voor toegang tot duizenden zorgvuldig samengestelde premiumverhalen en meer dan 9000 tijdschriften en kranten.
Bent u al abonnee? Aanmelden
MEER VERHALEN VAN BioSpectrum Asia
BioSpectrum Asia
Vietnam Rises as a Key Pharmerging Market
Vietnam is emerging as one of Asia's most promising pharmaceutical and biotechnology markets. As the government advances its national pharma strategy and regional collaborations deepen, the country is positioning itself as a future hub for biotech in Southeast Asia. We look at how the key trends are shaping Vietnam's pharma and biotech sectors from regulatory reforms and investment flows to the rise of local innovators.
4 mins
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Mind Over Matter: Decoding China's BCI Push
Once popularised by Elon Musk's Neuralink, brain-computer interface (BCI) technology is now drawing major interest in China. We now look at how the country is stepping up research and investment to advance its own BCI ecosystem.
6 mins
BioSpectrum Asia Nov 2025
BioSpectrum Asia
'Point of care will change the CDMO business structure from Centralised to De-Centralised cell manufacturing”
With Japan emerging as a hub for regenerative medicine innovation, Teijin Regenet—a Teijin Group company— has become a key player driving next-generation manufacturing and CDMO growth.
2 mins
BioSpectrum Asia Nov 2025
BioSpectrum Asia
EXPEDITING APPROVALS OF SAFE & AFFORDABLE BIOSIMILARS
While the world is discussing and troubled over 100 per cent tariffs on medicines announced just over a month back by the US administration, there is a music played to the ear of pharma producers in Asia. This music was played by the US Food and Drug Administration (FDA) last week when it made a major announcement over approvals of biosimilars, generic versions of complex biological drugs, that treat serious and chronic diseases.
2 mins
BioSpectrum Asia Nov 2025
BioSpectrum Asia
India signs MoU with Pfizer to strengthen healthcare innovation ecosystem
In a significant step towards strengthening India's healthcare innovation ecosystem, the Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, Government of India, has signed a Memorandum of Understanding (MoU) with US-based Pfizer Limited.
1 min
BioSpectrum Asia Oct 2025
BioSpectrum Asia
New Zealand to lead new gene therapy trial for muscular dystrophy
The first clinical trial of a new treatment for a rare form of muscular dystrophy is being led by New Zealand-based University of Auckland's Centre for Brain Research.
1 min
BioSpectrum Asia Oct 2025
BioSpectrum Asia
Scientists in Australia grow living skin in world-first
Australia's University of Queensland (UQ) researchers have been the first in the world to successfully grow fully functioning human skin in a laboratory.
1 min
BioSpectrum Asia Oct 2025
BioSpectrum Asia
India joins Health AI Global Regulatory Network to strengthen oversight of AI in healthcare
HealthAI - The Global Agency for Responsible AI in Health, has welcomed India as a pioneer country joining the HealthAI Global Regulatory Network (GRN), a global network of health regulators dedicated to the safe and effective use of artificial intelligence (AI) in healthcare.
1 min
BioSpectrum Asia Oct 2025
BioSpectrum Asia
TVM Capital Healthcare announces first closing of $150 M Southeast Asia Fund
Singapore-based TVM Capital Healthcare, a global private equity investor and operator specialised in healthcare growth capital across emerging markets, has announced the first closing of its $150 million TVM Healthcare Southeast Asia Fund (SEA Fund).
1 min
BioSpectrum Asia Oct 2025
BioSpectrum Asia
National Yang Ming Chiao Tung University, TSH Biopharm collaborate to foster pharma talent in Taiwan
Taiwan's National Yang Ming Chiao Tung University (NYCU) and TSH Biopharm have signed a five-year industry-academia collaboration Memorandum of Understanding (MOU).
1 min
BioSpectrum Asia Oct 2025
Listen
Translate
Change font size
